Clinical Trial Update: Testing of ADI-PEG in Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update indicating completion of testing of ADI-PEG 20 in hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• ADI-PEG 20 (pegylated arginine deiminase)

Snippet

Sponsor: FDA Office of Orphan Products Development | Conditions: Carcinoma, Hepatocellular | Phase 2 | Status: COMPLETED